News - Diabetes

Filter

Current filters:

Diabetes

Popular Filters

1 to 25 of 436 results

Xultophy, Accofil and Busulfan recommended by EMA/CHMP

26-07-2014

At its July 2014 meeting, the European Medicines Agency’s Committee for Medicinal Products for Human…

AccofilAccord HealthcareBiosimilarsBusulfanDiabetesEuropeFresenius KabiImmunologicalsNovo NordiskOncologyPharmaceuticalRegulationXultophy

A$35 million to advance Australian type 1 juvenile diabetes research

A$35 million to advance Australian type 1 juvenile diabetes research

10-07-2014

Australia’s Minister for Education, Christopher Pyne, and Minister for Health, Peter Dutton, have today…

AustraliaDiabetesFinancialPharmaceuticalResearch

China’s Yabao Pharma partners with Eli Lilly to develop diabetes candidate

China’s Yabao Pharma partners with Eli Lilly to develop diabetes candidate

08-07-2014

Chinese drugmaker Yabao Pharmaceutical has entered a strategic partnership with US pharma major Eli Lilly…

ChinaDiabetesEli LillyLicensingPharmaceuticalYabao Pharmaceutical

SMC guidance on AstraZeneca’s diabetes drug and Roche’s MabThera

SMC guidance on AstraZeneca’s diabetes drug and Roche’s MabThera

08-07-2014

The Scottish Medicines Consortium (SMC) has issued guidance on Anglo-Swedish drug major AstraZeneca’s…

AstraZenecaBiotechnologydapagliflozinDiabetesMabTheraOncologyRocheUK

Sanofi's NDA for basal insulin Toujeo accepted by FDA

Sanofi's NDA for basal insulin Toujeo accepted by FDA

08-07-2014

The US Food and Drug Administration has accepted for review French pharma major Sanofi’s New Drug Application…

DiabetesPharmaceuticalRegulationSanofiToujeoUSA

Glowing prospects for Novo Nordisk's insulin degludec/liraglutide for type 2 diabetes

Glowing prospects for Novo Nordisk's insulin degludec/liraglutide for type 2 diabetes

07-07-2014

Danish diabetes care giant Novo Nordisk's fixed-dose combination therapy insulin degludec/liraglutide…

DiabetesEuropeIDegLiraMarkets & MarketingNovo NordiskPharmaceuticalUSAXultophy

Japan marketing approval for Canaglu; vaccine license for Daiichi Sankyo

Japan marketing approval for Canaglu; vaccine license for Daiichi Sankyo

04-07-2014

Japanese drug major Mitsubishi Tanabe Pharma has received approval to manufacture and market the SGLT2…

canagliflozinCanagluDaiichi SankyoDiabetesJapanMitsubishi TanabePharmaceuticalRegulationSanofi PasteurVaccines

FDA approves MannKind’s Afrezza to treat diabetes

FDA approves MannKind’s Afrezza to treat diabetes

30-06-2014

In a much awaited decision, the US Food and Drug Administration on Friday approved MannKind Corp’s…

AfrezzaDiabetesMannKindPharmaceuticalRegulationUSA

ImmuPharma extends research capabilities via French connection

27-06-2014

UK-based drug discovery firm ImmuPharma has extended its research capabilities by setting up its own…

DiabetesImmuPharmaPharmaceuticalResearchUrelix

FDA review of CV risks for diabetics taking olmesartan not conclusive

FDA review of CV risks for diabetics taking olmesartan not conclusive

25-06-2014

The US Food and Drug Administration has completed its safety review and has found no clear evidence of…

BenicarCardio-vascularDaiichi SankyoDiabetesolmesartanPharmaceuticalRegulationUSA

UK’s NICE approves Janssen’s Invokana for type 2 diabetes

UK’s NICE approves Janssen’s Invokana for type 2 diabetes

25-06-2014

The UK’s National Institute for Health and Care Excellence (NICE) has issued new final guidance recommending…

DiabetesInvokanaJanssenPharmaceuticalRegulationUK

Positive new Ph IIIa data on Novo Nordisk’s liraglutide

Positive new Ph IIIa data on Novo Nordisk’s liraglutide

23-06-2014

New data for Danish diabetes care giant Novo Nordisk’s liraglutide 3mg from the Phase IIIa SCALET Obesity…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearch

Novo Nordisk launch new insulin device Levemir FlexTouch in USA

Novo Nordisk launch new insulin device Levemir FlexTouch in USA

19-06-2014

Danish diabetes care giant Novo Nordisk has launched its newest prefilled insulin delivery device Levemir…

DiabetesLevemirMarkets & MarketingNovo NordiskPharmaceuticalUSA

Boehringer and Lilly re-file empagliflozin NDA with FDA

Boehringer and Lilly re-file empagliflozin NDA with FDA

19-06-2014

The US subsidiary of German family-owned drugmaker Boehringer Ingelheim and pharma major Eli Lilly have…

Boehringer IngelheimDiabetesEli LillyempagliflozinPharmaceuticalRegulationUSA

Added benefit of Invokana in type 2 diabetes is not proven, says IQWiG

Added benefit of Invokana in type 2 diabetes is not proven, says IQWiG

17-06-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

DiabetesGermanyInvokanaJanssen-CilagJohnson & JohnsonPharmaceuticalPricingRegulation

ADA 2014: New data on Novo Nordisk’s IDegLira and Victoza

ADA 2014: New data on Novo Nordisk’s IDegLira and Victoza

15-06-2014

A new Phase IIIa study shows that IDegLira, the once-daily single injection combination of Danish diabetes…

DiabetesIDegLiraNovo NordiskPharmaceuticalResearchVictoza

ADA 2014: Positive Ph III Results for Sanofi’s Toujeo

ADA 2014: Positive Ph III Results for Sanofi’s Toujeo

15-06-2014

French pharma major Sanofi has released data from a pooled analysis, investigational therapy Toujeo (insulin…

DiabetesPharmaceuticalResearchSanofiToujeo

ADA 2014: GSK presents new data for once-weekly Tanzeum in type 2 diabetes

ADA 2014: GSK presents new data for once-weekly Tanzeum in type 2 diabetes

15-06-2014

Patients enrolled in of four randomized Phase III studies who remained on Tanzeum/Eperzan (albiglutide),…

Anti-diabetic drugsDiabetesGlaxoSmithKlineGSKMajorPharmaceuticalResearchStudy protocolStudy protocolTanzeumUK

Large increase seen in insulin use, out-of-pocket costs for type 2 diabetes

11-06-2014

Largely attributable to the widespread adoption of insulin analogs, use of insulin among patients with…

DiabetesHealthcarePharmaceuticalPricingUSA

6,000 new jobs in Novo Nordisk create a further 15,000 jobs in Denmark

6,000 new jobs in Novo Nordisk create a further 15,000 jobs in Denmark

11-06-2014

Up to 2022, Danish diabetes care giant Novo Nordisk expects to hire 6,000 new employees in Denmark, half…

BoardroomDenmarkDiabetesManagementNovo NordiskPharmaceutical

1 to 25 of 436 results

Back to top